Premium
Hospitalization for serious blood and skin disorders following co‐trimoxazole
Author(s) -
Wald Myers Marian,
Jick Hershel
Publication year - 1997
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1997.00590.x
Subject(s) - discontinuation , medicine , toxic epidermal necrolysis , cohort , pediatrics , cohort study , population , dermatology , environmental health
Aims To quantify the risk of serious blood and skin disorders requiring hospitalization among otherwise healthy users of co‐trimoxazole Methods We conducted a population‐based cohort study at Group Health Cooperative of Puget Sound (GHC). Results During the years 1987 to 1993 we found six cases of co‐trimoxazole‐associated blood disorders and three cases of co‐trimoxazole‐associated skin disorders yielding risks of 5.6/100,000 (95% CI 2.6–12.2) and 2.8/100,000 (95% CI 0.9–8.2) respectively. In all cases found there was prompt recovery after discontinuation of co‐trimoxazole. We found no cases of toxic epidermal necrolysis. Conclusions We conclude that the risk of blood and skin disorders associated with the use of co‐trimoxazole leading to hospitalization is low.